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Abstract
The migration of the human pathogen Streptococcus pyogenes (group A streptococcus) from localized to
deep tissue sites may result in severe invasive disease, and sequestration of the host zymogen
plasminogen appears crucial for virulence. Here, we describe a novel plasminogen-binding M protein, the
plasminogen-binding group A streptococcal M protein (PAM)-related protein (Prp). Prp is phylogenetically
distinct from previously described plasminogen-binding M proteins of group A, C, and G streptococci.
While competition experiments indicate that Prp binds plasminogen with a lower affinity than PAM (50%
effective concentration = 0.34 µM), Prp nonetheless binds plasminogen with high affinity and at
physiologically relevant concentrations of plasminogen (Kd = 7.8 nM). Site-directed mutagenesis of the
putative plasminogen binding site indicates that unlike the majority of plasminogen receptors, Prp does
not interact with plasminogen exclusively via lysine residues. Mutagenesis to alanine of lysine residues
Lys96 and Lys101 reduced but did not abrogate plasminogen binding by Prp. Plasminogen binding was
abolished only with the additional mutagenesis of Arg107 and His108 to alanine. Furthermore,
mutagenesis of Arg107 and His108 abolished plasminogen binding by Prp despite the presence of Lys96
and Lys101 in the binding site. Thus, binding to plasminogen via arginine and histidine residues appears
to be a conserved mechanism among plasminogen-binding M proteins.
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The Plasminogen-Binding Group A Streptococcal M ProteinRelated Protein Prp Binds Plasminogen via Arginine and Histidine
Residues_
Martina L. Sanderson-Smith, Mark Dowton, Marie Ranson, and Mark J. Walker*
School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522,
Australia

ABSTRACT
The migration of the human pathogen Streptococcus pyogenes (group A
streptococcus) from localized to deep tissue sites may result in severe invasive
disease, and sequestration of the host zymogen plasminogen appears crucial for
virulence. Here, we describe a novel plasminogen-binding M protein, the
plasminogen-binding group A streptococcal M protein (PAM)-related protein (Prp).
Prp is phylogenetically distinct from previously described plasminogen-binding M
proteins of group A, C, and G streptococci. While competition experiments indicate
that Prp binds plasminogen with a lower affinity than PAM (50% effective
concentration = 0.34 µM), Prp nonetheless binds plasminogen with high affinity
and at physiologically relevant concentrations of plasminogen (Kd = 7.8 nM). Sitedirected mutagenesis of the putative plasminogen binding site indicates that unlike
the majority of plasminogen receptors, Prp does not interact with plasminogen
exclusively via lysine residues. Mutagenesis to alanine of lysine residues Lys96 and
Lys101 reduced but did not abrogate plasminogen binding by Prp. Plasminogen
binding was abolished only with the additional mutagenesis of Arg107 and His108 to
alanine. Furthermore, mutagenesis of Arg107 and His108 abolished plasminogen
binding by Prp despite the presence of Lys96 and Lys101 in the binding site. Thus,
binding to plasminogen via arginine and histidine residues appears to be a
conserved mechanism among plasminogen-binding M proteins.

INTRODUCTION
The gram-positive bacterium Streptococcus pyogenes (group A streptococcus [GAS]) is
the major pathogenic agent of a wide variety of skin and mucosal infections in humans.
Current estimates indicate that approximately 1.78 million new cases of severe
streptococcal infection emerge each year (5). A key feature of invasive GAS infections is
the ability of the organism to migrate from cutaneous and mucosal surfaces to deep tissue
sites, resulting in severe invasive disease. While the exact mechanisms by which GAS
cross host tissue barriers are yet to be fully elucidated, sequestration of plasminogen by
GAS is being increasingly implicated in the pathogenesis of this organism (32). Indeed,
for a subset of GAS isolates, acquisition of plasminogen via cell surface receptors
appears to be crucial for virulence (6, 30). Plasminogen is a single-chain glycoprotein
found in plasma and extracellular fluids at concentrations of approximately 2 µM (8).
Specific mammalian plasminogen activators cleave plasminogen at a single site (Arg560Val561), resulting in the formation of the two-chain plasmin molecule, which contains a
serine protease active site in the C-terminal region. Plasmin(ogen) typically interacts with
its ligands via lysine binding sites located in the five kringle domains of the N terminus
of plasminogen (21). Plasmin(ogen) receptors and activators have been found to be
expressed by a large number of bacteria, including group A, C, and G streptococci (15).
In addition to the secreted nephritogenic plasminogen-binding protein (22), three cell
surface-expressed GAS plasminogen-binding proteins have been identified. These are
streptococcal surface enolase (SEN) (18), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (4, 19), and the plasminogen-binding group A streptococcal M protein (PAM)
(3). Furthermore, the secreted protein streptokinase enables GAS to activate plasminogen

to plasmin (15). Plasmin has the ability to degrade fibrin clots, connective tissue, and the
extracellular matrix (8, 21). Thus, sequestration of this proteolytic system by GAS may
have significant pathological consequences in the host. Coded for by the emm gene, M
protein is one of the major virulence factors of GAS. The emm family of genes consists
of emm, mrp, and enn genes (12). The N termini of M proteins consist of a highly
variable region, followed by a series of repeat domains designated a, b, c, and d. The
number and type of repeats vary significantly between different M proteins (7, 16). Here
we describe a novel, high-affinity plasminogen-binding M protein, the PAM-related
protein Prp. Associated with an S. pyogenes emm 98.1 strain isolated from a severe
invasive infection and which displays high levels of cell surface plasminogen binding
(17), Prp is phylogenetically distinct from previously characterized plasminogen-binding
M proteins. Using site-directed mutagenesis we show that, like PAM, Prp binds
plasminogen via arginine and histidine residues, rather than lysine residues, which
commonly mediate the interaction of plasminogen with its many other receptors.

MATERIALS AND METHODS

Bacterial strains and culture methods. Group A streptococcal strains were grown on
horse blood agar plates (American Diagnostica) or cultured overnight at 37°C in ToddHewitt broth (Difco Laboratories) containing 1% yeast extract. All streptococcal strains
used in this study were collected from the Northern Territory of Australia and have been
described previously (17, 26). Escherichia coli INVFα containing pCR2.1/Prp constructs
(17) or E. coli TOP10 containing expression plasmids was grown on Luria-Bertani (LB)

agar plates or cultured in LB broth supplemented with ampicillin (100 µg/ml) as
described previously (25). Plasmid DNA was extracted for PCR and DNA sequence
analysis using the Wizard Plus SV DNA purification kit (Promega).
Phylogenetic analysis. In order to characterize the evolutionary relationships between
Prp and naturally occurring variants of the PAM protein, the full amino acid sequences of
12 previously identified PAM proteins and Prp (17) were aligned using ClustalW (31).
Evolutionary gene trees were then estimated using MrBayes version 3.1 (13, 24). For the
MrBayes analysis, four simultaneous chains were run, with trees sampled every 100
generations for a total of 500,000 generations. Plots of likelihood scores against
generation were used to identify when the analysis had reached stationarity. Trees
sampled prior to stationarity (the first 40 trees) were discarded. The amino acid model
was empirically chosen by MrBayes, using the prset aamodelpr = mixed command. This
permits jumping between nine alternative amino acid substitution models. The WAG
model (33) was empirically chosen by MrBayes. The majority rule consensus of all trees
generated after stationarity was used to estimate the posterior probabilities of the various
nodes in the most likely tree.
DNA sequence analysis, expression, and purification of recombinant M proteins.
The Prp gene from GAS strain NS88.2 had previously been cloned into the vector
pCR2.1 (17). Primer sequences used for DNA sequence analysis are available upon
request. DNA sequence reactions were undertaken using terminator ready reaction mix
(PE Applied Biosystems). DNA sequencing gels were prepared as per the manufacturer’s
instructions and electrophoresed using a Perkin-Elmer ABI PRISM 377 sequencer.
Sequence data were analyzed using ABI Prism DNA sequencing analysis software

(Perkin-Elmer). To facilitate functional analysis, Prp was cloned into the expression
vector pGEX-2T essentially as previously described (26). Briefly, the Prp gene was
amplified from a pCR2.1 construct by using Pfu polymerase (Stratagene). PCR cycling
parameters consisted of 30 cycles of 97°C, 55°C, and 72°C for denaturation, annealing,
and extension reactions, respectively. Amplicons were cloned into pGEX-2T (29),
resulting in an N-terminal fusion with glutathione S-transferase, and constructs were
transformed into E. coli TOP10 (Invitrogen) by standard procedures (25). The presence
of both a His6 tag and a glutathione S-transferase tag on the recombinant protein enabled
purification by two methods. DNA sequence analysis was used to confirm the lack of
PCR errors in the cloned amplification product. Recombinant proteins were expressed
and purified as described previously (26). Each step of the protein purification process
was monitored by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) analysis (14), with protein visualized using Coomassie blue R250 staining.
Site-directed mutagenesis. Sequence alignment of Prp with other plasminogenbinding
M proteins identified a potential plasminogen binding site within the molecule. In order
to confirm the role of specific residues within this region in the interaction of Prp with
plasminogen, site-specific mutations were introduced into the putative binding site. The
wild-type pGEX-2T construct (100 ng) was used as template DNA to create site-directed
mutants with the QuikChange site-directed mutagenesis kit (Stratagene). PCR mixtures
consisted of 1PFU reaction buffer (Stratagene), 0.25mMdeoxynucleoside triphosphates
(Boehringer Mannheim, Germany), 2.5Uof Pfu Ultra polymerase (Stratagene), and 125
ng of each primer, madeup to a volume of 50 µl with distilled water. Oligonucleotide
primers (Sigma-Aldrich) were designed as per the manufacturer’s instructions

(Stratagene). In general, primers consisted of sequence encoding the desired mutation,
flanked on either side by 15 nucleotides of wild-type sequence. The specific primer
sequences are available upon request. For site-directed mutants containing more than two
mutations not encoded by a single primer, alanine residues were sequentially introduced
using previously mutated DNA as a template. Following an initial denaturation step
(95°C, 30 s), PCR cycling parameters consisted of 16 cycles of 95°C for 30 s, 55°C for 1
min, and 68°C for 10 min. An additional 7-min extension at 55°C was then performed.
PCR was conducted with a Cooled Palm 96 thermocycler (Corbett Research).
Nonamplified template DNA was removed by incubation of reaction mixtures for 1 h at
37°C following the addition of DpnI (10 U/50-µl reactionmixture). E. coli TOP10
(Invitrogen) was transformed with 150 ng of DpnI-digested PCR product by standard
procedures (25).
CD spectroscopy. To highlight potential variation in protein secondary structureas a
result of site-directed mutagenesis, far-UV circular dichroism (CD) spectra were obtained
for both wild-type and mutant recombinant proteins. CD spectra were acquired using a
Jasco J-810 spectropolarimeter (Jasco, Canada) at room temperature. CD spectral data
were recorded from 190 to 250 nm in a 1-cm-path-length cell containing 1.5 ml of protein
solution at a concentration of 0.04 mg/ml in 10 mM sodium phosphate buffer (pH 7.4).
Recorded data represent the averages of six scans, corrected for buffer baseline. Molar
residue ellipticity ([θ]) was calculated using the following formula: [θ]=θ  100 
molecular weight/concentration (mg/ml)  distance  number of amino acids (28). The
percentage of α-helices was estimated from the ellipticity at 222 nm using the following
formula: percent α-helix = -(θ 222 nm - 4,800)/45,400 (20).

Plasminogen purification and labeling. Glu-plasminogen, the circulating form of
plasminogen, was purified from human plasma by using lysine Sepharose 4B affinity
chromatography as described previously (1, 26). Purified plasminogen was biotinylated
by the addition of 10% (vol/vol) 1 M NaHCO3 (pH 9), and a 40 molar excess of biotinX-N-hydroxysuccinimide in dimethyl sulfoxide (Sigma-Aldrich). The reaction mixture
was incubated at 4°C overnight with mixing. Free biotin was separated from biotinylated
plasminogen by PD-10 gel filtration chromatography (Amersham Biosciences).
Plasminogen binding analysis. Solid-phase plasminogen binding assays were performed
in order to assess both the affinity of Prp for plasminogen and the impact of introduced
mutations on protein function, essentially as previously described (26). Ninety-six-well
microtiter plates (Greiner Bio-one, Germany) were coated with 150 nM recombinant
protein (50 µl in 0.1 M NaHCO3) at 4°C overnight. Following three washes with PiNT
(50 mM Na2HPO4, 150 mM NaCl, 0.05% Tween 80, pH 7.5), plates were blocked with
50 µl of blocking solution (1% skim milk powder in PiNT) for 1 h at 37°C. Wells were
washed as described above, and 500 nM biotinylated glu-plasminogen was diluted in a
threefold titration across the plate with blocking buffer in the presence or absence of a
50-fold molar excess of unlabeled glu-plasminogen. Plasminogen was allowed to bind to
immobilized proteins for 2 h at room temperature. For competition assays, decreasing
concentrations of unlabeled fluid-phase PAMNS13 (25 µM to 0.14 nM) or wild-type Prp
were allowed to compete with immobilized proteins for binding to biotinylated gluplasminogen. Competitor was titrated threefold across the microtiter plate prior to the
addition of biotinylated glu-plasminogen to all wells, at a final concentration of 500 nM.
The assay mixture was incubated for 2 h at room temperature. Following the plasminogen

incubation step, microtiter plates were washed three times, and 50 µl of neutravidin
conjugated to horseradish peroxidase (Progen, Australia) diluted 1:5,000 with blocking
solution was added to all wells and incubated for 2 h at room temperature. After five
washes with PiNT, the reactions were developed by the addition of 50 µl ophenylenediamine (Sigma-Aldrich) substrate (8 mM Na2HPO4 [pH 5.0], 2.2 mM ophenylenediamine, 3% H2O2). Color development was stopped by the addition of 50 µl
of 10 M hydrochloric acid, and the plates were read at 490 nm using a Spectramax 250
plate reader (Molecular Devices). Data were normalized against the highest and lowest
absorbance value for each assay, and nonlinear regression analysis was performed using
GraphPad Prism (v4.00; GraphPad Software, CA). For the calculation of equilibrium
binding dissociation constants (Kd), a one- versus two-site binding analysis was
conducted and the best-fit curve fitted to the data. For competition experiments, a onesite competition curve was fitted to the data, from which the effective concentration of
competitor required to inhibit binding by 50% was calculated.
Statistical analysis. For plasminogen binding experiments, a one-way analysis of
variance was initially used on all data, followed by an unpaired t test with Welsch’s
correction to determine if there was any significant difference in the Kd values obtained
for various proteins in this study.
Nucleotide sequence accession number. The Prp gene sequence has been submitted to
the NCBI database and assigned GenBank accession number AY351856.

RESULTS
Phylogenetic analysis. Isolated from a bacteremia infection, GAS strain NS88.2 encodes
a PAM-related M protein (Prp) that is only 66.4% identical to PAM if the conserved Crepeat domain is excluded. Phylogenetic analysis of Prp and a subset of group A, C, and
G streptococcal plasminogen-binding M proteins indicates that Prp is a phylogenetically
distinct molecule (Fig. 1). All of the PAM variants share a common ancestor that does
not include Prp, suggesting that Prp diverged early during the evolution of PAM and the
PAM-related proteins.
Plasminogen binding analysis. In order to confirm that Prp functions as a high-affinity
plasminogen receptor, plasminogen binding analysis of recombinant Prp was undertaken.
Recombinant Prp was expressed and purified using glutathione-agarose and Ninitrilotriacetic acid agarose affinity chromatographies. Recombinant PAMNS13 and the
NS696 M1 protein were also purified for use as positive and negative controls,
respectively, in plasminogen binding studies (Fig. 2A). PAMNS13 is 100% identical to
the prototype PAM protein in the a1 and a2 repeat region and has previously been shown
to interact with glu-plasminogen with high affinity, while the NS696 M1 protein displays
only nonspecific binding affinity for plasminogen (26). Ligand blot analysis indicated
that the 43-kDa recombinant Prp molecule interacts with biotinylated glu-plasminogen
(Fig. 2B). The interaction between recombinant Prp and glu-plasminogen was further
characterized using solid-phase plasminogen binding assays. Immobilized Prp bound
plasminogen in a dose-dependent fashion, and saturable binding was achieved with 500
nM plasminogen after 2 h (Fig. 3A). This is comparable to the binding of plasminogen by

the positive control protein PAMNS13 (Fig. 3B). Only nonspecific binding was found for
the negative control NS696 M1 protein (Fig. 3C).

Best-fit nonlinear regression analysis determined the equilibrium dissociation constant
(Kd) for the interaction of Prp with glu-plasminogen to be 7.6 nM. The interaction
between Prp and plasminogen is therefore significantly lower than that of PAMNS13
with plasminogen (Kd = 1.6 nM; P = 0.02). To further explore the relative affinity of Prp
for plasminogen compared to PAM, Prp binding to biotinylated plasminogen was
competed with various concentrations of unlabeled fluidphase PAMNS13. The effective
concentration of competitor required to inhibit plasminogen binding by 50% was found to
be 0.34 µM, as determined by fitting a one-site competition curve (Fig. 4). This confirms
that Prp has a lower affinity for plasminogen than PAM. Nonetheless, the binding of
plasminogen by Prp with a Kd of 7.6 nM represents a high-affinity, physiologically
relevant interaction.
Binding site characterization. The major site of variation between Prp and the prototype
PAM protein lies between residues 29 and 100 in the N terminus of Prp. This sequence
includes a region of 21 amino acids, with 52% identity to the plasminogen binding site of
PAM (17), which may function as a plasminogen binding domain within the Prp
molecule. This putative plasminogen binding domain appears to consist of a single
binding site comprised of 21 amino acids (Fig. 5A), in contrast to the a1 and a2 repeats
found to mediate plasminogen binding by PAM (3). In order to confirm the role of this
potential binding site in the interaction of Prp with plasminogen and to identify the
specific residues which mediate binding, a series of site-directed mutants in which

selected binding site residues were mutated to alanine was constructed. The binding-site
sequences of the site-directed mutants are given in Fig. 5B. Plasminogen typically binds
to internal and C-terminallysine residues, and thus lysine residues Lys96 and Lys101 were
mutated to alanine. Additionally, PAM is able to mediate high-affinity plasminogen
binding via internal residues Arg101, His102, Arg114, and His115 (27). Therefore, residues
Arg107 and His108 were also selected for mutagenesis. The impact of mutations in the
plasminogen binding domain of Prp on protein structure was analyzed using far-UV CD
spectroscopy. All site-directed mutants used in this study were found to have a CD
emission spectrum similar to that of wild-type Prp, displaying two characteristic minima
at approximately 210 nm and 220 nm and a maximum peak at 190 nm (data not shown).
This is similar to the CD spectra of other streptococcal M proteins, which are coiled-coil
α-helical proteins (20). Thus, even after mutagenesis these proteins appear to maintain an
_-helical secondary structure. Additionally, for all proteins the two minima are of a
similar magnitude, which is indicative of coiled-coil proteins (9, 10). The percent αhelicity ranged from 37% to 43%. These data confirm that these proteins are structurally
similar and that site-directed mutagenesis has resulted in minimal changes to secondary
structure.

In order to determine the impact of site-directed mutagenesis on plasminogen binding by
Prp, plasminogen binding analysis was conducted. Wild-type Prp and Prp[K96 K101] both
interacted with biotinylated glu-plasminogen in a ligand blot analysis. No interaction with
Prp[K96K101R107H108] or Prp [R107H108] was seen (Fig. 6). This suggests that the
interaction of Prp with glu-plasminogen is mediated by residues Arg107 and His108. To

further characterize the role of these residues in plasminogen binding and to determine
the specificity of Prp[K96K101] plasminogen binding, solid-phase plasminogen binding
assays were conducted using the site-directed mutant Prp proteins. None of the sitedirected mutants interacted in a specific, saturable fashion with 500 nM plasminogen
(Fig. 7). Prp[K96K101] approached but did not reach saturation (Fig. 7). Indeed, in the
presence of 500 nM plasminogen, wild-type Prp was found to interact specifically with
approximately 80% of the available labeled plasminogen. In contrast, Prp[K96K101] shows
only 50% specific binding at the same plasminogen concentration. This suggests that this
protein is still able to mediate a lower-affinity interaction with plasminogen, in spite of
the absence of lysine residues. Only nonspecific binding was found for site-directed
mutants Prp[K96K101R107H108] and Prp[R107H108]. Thus, it appears that residues Arg107 and
His108 are indispensable for mediation of the high-affinity interaction of Prp with
plasminogen.

DISCUSSION
Prp functions as a high-affinity receptor for glu-plasminogen, as evidenced by the
plasminogen binding data presented here. To date, PAM has been reported to have the
highest affinity of the known GAS plasminogen receptors for glu-plasminogen (Kd 1
nM) (3, 26). While the interaction of Prp with gluplasminogen is of a lower affinity than
that of PAM (Kd = 7.8nM), Prp binds plasminogen specifically. Furthermore, circulating
concentrations of glu-plasminogen are approximately 2 µM, and thus the interaction of
Prp with plasminogen is within physiologically relevant concentrations of the zymogen
(8).

Plasminogen typically binds to receptors via C-terminal orinternal lysine residues, as
exemplified by the previously characterized GAS plasminogen receptors SEN and
GAPDH. Binding of plasminogen to SEN occurs via residues Lys434 and Lys435 at the C
terminus of the SEN molecule, while binding of plasminogen to GAPDH occurs via the
C-terminal lysine Lys334 (4, 18). In contrast, plasminogen binding to PAM has been
attributed to internal lysine residues Lys98 and Lys111(3, 34, 35). However, it has recently
been demonstrated that PAM mediates its interaction with plasminogen via arginine and
histidine residues within two internal repeat domains (27). Mutation of lysine residues
within a putative Prp plasminogen binding site (Lys96 and Lys101) did not result in the
abrogation of plasminogen binding. While mutation of these residues reduced the affinity
of Prp for plasminogen, binding was fully eliminated only following the mutation of
residues Arg107 and His108 to alanine. Indeed, the finding that plasminogen binding was
eliminated even in the presence of lysine residues highlights the role of residues Arg107
and His108 in mediating the interaction of Prp with plasminogen. Changes in plasminogen
binding by site-directed mutants do not appear to result from protein structural changes,
as far-UV CD analysis of site-directed mutants indicates that these molecules are
structurally similar to the wild-type Prp. The percent α-helicity for mutants reported here
was between 37% and 43%. CD analysis of other streptococcal M proteins has found
them to contain between 23% and 70% α-helices (20). This demonstrates that despite the
phylogenetic differences between PAM and Prp, both interact with plasminogen via a
common mechanism which is distinct from the interaction of other plasminogen-binding
proteins.

X-ray crystallography analysis of a 30-amino-acid peptide has shown that arginine and
histidine residues, when correctly presented in an alpha-helical molecule, are able to
make numerous salt bridge and hydrophobic electrostatic interactions with recombinant
kringle 2 of plasminogen, forming a pseudoligand similar to the lysine analogue ε-amino
caproic acid (23). It is conceivable that the residues Arg107 and His108 within Prp interact
with plasminogen in a similar fashion. Thus, the binding site of Prp can be localized to a
single domain within the N terminus of the protein encompassing residues Arg107 and
His108.

Recent findings that the acquisition of plasminogen by S. pyogenes may be crucial for the
virulence of certain strains of GAS (6, 30), and the ability of multiple GAS proteins to
facilitate this process, necessitate a deeper understanding of the mechanisms via which
GAS interacts with plasminogen. This study identifies a novel plasminogen-binding M
protein which interacts with plasminogen via arginine and histidine residues within a
single binding domain. While lysine residues within this domain do appear to contribute
partially to this interaction, they are not the primary residues by which plasminogen
binds, in contrast to findings for other GAS plasminogen receptors. The finding that
multiple M proteins with plasminogen binding ability have evolved separately is
indicative of the selective advantage that plasminogen binding confers upon GAS and
supports the suggestion that interaction with the host plasma protein plasminogen may be
important for the virulence of certain strains of GAS. Plasminogen binding by arginine
and histidine residues has, to date, been reported only for GAS plasminogen-binding M
proteins. This interaction may represent a novel way in which the bacterium binds to the

low-affinity kringle 2 of plasminogen, thereby avoiding competition with other abundant
host proteins and inhibitors. The apparent advantage conferred on GAS by its ability to
interact with the host plasminogen activation system via a number of receptors has
widespread implications for both the study and treatment of GAS pathogenesis and
infection.
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FIGURE LEGENDS
FIG. 1. Phylogeny generated by Bayesian analysis of the amino acid sequences of 13
PAM genes (PAMNS13, GenBank accession no. AY351851; PAMNS455, GenBank
accession no. AY351857; PAMNS265, GenBank accession no. AY351855; PAMNS223,
GenBank accession no. AY351854; PAMNS253, GenBank accession no. AY351853;
PAMNS53, GenBank accession no. AY351852; PAMNS32, GenBank accession no.
AY351850; PAMNS50.1, GenBank accession no. AY351849; PAMNS59, GenBank
accession no. AY351848; PAMNS1133, GenBank accessionno. AY351847; PAMNS10,
accession no. GenBank AY351846; PAMNS221, GenBank accession no. DQ136319;
NS696 M1 protein, GenBank accessionno. AY351858; and Prp, GenBank accession no.
AY351856). MLC36 (GenBank accession no. Z32677) and MLC72 (GenBank accession
no. Z32678) are plasminogen-bindingMprotein sequences from group C andgroup G
streptococci, respectively (2). The M1 (11) and NS696 M1 proteinsequences were
included as outgroups.

FIG. 2. SDS-PAGE and ligand blot analysis of recombinant M proteins. (A) SDS-12%
polyacrylamide gel showing the purified recombinant proteins PAMNS13 (lane 1), Prp
(lane 2), and NS696 M1 (lane 3). Molecular mass markers are given in kilodaltons. (B)
Ligand blot analysis employing biotinylated glu-plasminogen of purified recombinant
proteins PAMNS13 (lane 1), Prp (lane 2), and NS69 6 M1 (lane 3). Molecular mass
markers are given in kilodaltons.

FIG. 3. Saturation binding analysis of biotinylated glu-plasminogen binding to
immobilized recombinant proteins. Biotinylated glu-plasminogen binding to immobilized
recombinant proteins Prp (A), PAMNS13 (B), and NS696 M1 protein (C) was measured in
the absence (▼, total binding) and presence (♦, nonspecific binding) of a 50-fold molar
excess of unlabeled glu-plasminogen. Specific binding (■) was determined by subtracting
nonspecific binding from total binding at each concentration. A one-site hyperbolic
binding function was fitted to the data (P < 0.05), from which the binding dissociation
constants were determined. Error bars represent the standard errors of the means.

FIG. 4. Competition of glu-plasminogen binding to immobilized .recombinant Prp with
fluid-phase PAMNS13. Binding of biotinylatedglu-plasminogen to immobilized Prp was
measured in the presence of various concentrations of unlabeled fluid-phase PAMNS13.
Data points are the mean values of triplicate readings, with error bars indicating standard
errors of the means. One-site competition analysis was used to determine the
concentration of PAMNS13 required to inhibit binding of biotinylated glu-plasminogen by
50%.

FIG. 5. (A) Translated DNA sequences of the plasminogen-binding region (a1/a2 repeats)
of the prototype PAM binding site with PAMNS13 and a putative 21-amino-acid residue
Prp plasminogen-binding site. *, residues identical to those of the PAM sequence; -, gaps
in the alignment. (B) Alignment of the plasminogen binding domain of wild-type Prp
with those of the three site-directed mutants constructed in this study. Mutated residues
are indicated in boldface.

FIG. 6. SDS-PAGE and ligand blot analysis of Prp site-directed mutants. (A) SDS-12%
polyacrylamide gel showing the purified recombinant proteins Prp (lane 1),
Prp[K96K101R107H108] (lane 2), Prp[K96K101] (lane 3), and Prp[R107H108] (lane 4).
Molecular mass markers are given in kilodaltons. (B) Ligand blot analysis employing
biotinylated glu-plasminogen of purified recombinant proteins Prp (lane 1),
Prp[K96K101R107H108] (lane 2), Prp[K96K101] (lane 3), and Prp[R107H108] (lane 4).
Molecular mass markers are given in kilodaltons.

FIG. 7. Specific binding of biotinylated glu-plasminogen to immobilized recombinant
proteins Prp (■), Prp[K96K101R107H108] (▼), Prp[K96K101] (●), and Prp[R107H108] (F).
Specific binding was determined by subtracting nonspecific binding from total binding at
each concentration. A one-site hyperbolic binding function was fitted to the data (P <
0.05), from which the binding dissociation constants were determined. Error bars
represent the standard errors of the means (n =3).
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